NCT05654181View on ClinicalTrials.gov

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Healthy
Interventions
DRUG

PF-07328948

investigational drug administered orally

DRUG

Placebo

Placebo matching active drug administered orally

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY